• OPEN AN ACCOUNT
Indian Indices
Sensex
76,863.71 -1,342.27
( -1.72%)
Global Indices
Nasdaq
47,431.94 -295.58
(-0.62%)
Dow Jones
6,795.43 -7.05
(-0.10%)
Hang Seng
55,018.23 769.84
(1.42%)
Nikkei 225
10,315.38 -96.86
(-0.93%)
Forex
USD-INR
92.14 0.30
(0.32%)
EUR-INR
106.58 -0.02
(-0.02%)
GBP-INR
123.09 0.04
(0.04%)
JPY-INR
0.58 0.00
(0.05%)

EQUITY - MARKET SCREENER

Eldeco Housing & Industries Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
523329
INE668G01021
348.6753788
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ELDEHSG
31.39
887.92
EPS(TTM)
Face Value()
Div & Yield %
28.77
2
1
 

Alkem Lab arm Enzene receives 6 observations after USFDA inspection
Feb 16,2026
At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations. Enzene has achieved zero observations related to data integrity – a critical validation of Enzen’s quality systems and the reliability of regulatory filings.

Enzene is currently preparing its response to the USFDA within the stipulated timeline and has initiated appropriate corrective and preventive actions to address the observations.

Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.

The company’s consolidated net profit rose 2% to Rs 653.53 crore in Q3 FY26, compared with Rs 640.79 crore posted in Q3 FY26. Net sales jumped 10.7% YoY to Rs 3,736.82 crore in the quarter ended 31 December 2025.

Shares of Alkem Laboratories added 1.38% to currently trade at Rs 5,475.85 on the BSE.